Search Results - "Tafuto, S"

Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) by Panzuto, F., Maccauro, M., Campana, D., Faggiano, A., Massironi, S., Pusceddu, S., Spada, F., Ferone, D., Modica, R., Grana, C. M., Ferolla, P., Rinzivillo, M., Badalamenti, G., Zatelli, M. C., Gelsomino, F., De Carlo, E., Bartolomei, M., Brizzi, M. P., Cingarlini, S., Versari, A., Fanciulli, G., Arvat, E., Merola, E., Cives, M., Tafuto, S., Baldari, S., Falconi, M.

“…Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management…”
Get full text

Folfiri-aflibercept vs folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice by Ottaiano, A, Capozzi, M, De Divitiis, C, Cassata, A, De Stefano, A, Tafuto, S, Avallone, A, Nasti, G

Get full text

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) by Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E., Li, D., Tafuto, S., Raj, N., Campana, D., Hijioka, S., Raderer, M., Guimbaud, R., Gajate, P., Pusceddu, S., Reising, A., Degtyarev, E., Mookerjee, B., Aimone, P., Singh, S.

Get full text

Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509) by Capdevila, J., Fazio, N., Lopez, C., Teule, A., Valle, J.W., Tafuto, S., Custodio, A., Reed, N., Raderer, M., Grande, E., Garcia-Carbonero, R., Jimenez Fonseca, P., Alonso, V., Antonuzzo, L., Spallanzani, A., Berruti, A., Sevilla Garcia, I., La Casta, A., Hernando, J., Ibrahim, T.

Get full text

A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial by von Arx, C., Della Vittoria Scarpati, G., Cannella, L., Clemente, O., Marretta, A.L., Bracigliano, A., Picozzi, F., Iervolino, D., Granata, V., Modica, R., Bianco, A., Mocerino, C., Di Mauro, A., Pizzolorusso, A., Di Sarno, A., Ottaiano, A., Tafuto, S.

“…There is no consensus on the second-line treatment of patients with progressive high-grade neuroendocrine neoplasms (NENs G3) and large-cell lung…”
Get full text

Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC) by Avallone, A., Nasti, G., Rosati, G., Carlomagno, C., Romano, C., Bilancia, D., De Stefano, A., Silvestro, L., Ottaiano, A., Cassata, A., Bianco, F., Izzo, F., Delrio, P., De Gennaro, E., Casaretti, R., Tafuto, S., Albino, V., Pace, U., Lastoria, S., Gallo, C., Budillon, A., Piccirillo, M.

Get full text

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma by De Divitiis, C, von Arx, C, Grimaldi, A M, Cicala, D, Tatangelo, F, Arcella, A, Romano, G M, Simeone, E, Iaffaioli, R V, Ascierto, P A, Tafuto, S

“…Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine…”
Get full text

Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS by Avallone, A., Nasti, G., Rosati, G., Carlomagno, C., Romano, C., Bilancia, D., De Stefano, A., Ottaiano, A., Cassata, A., Bianco, F., Del Rio, P., Izzo, F., Silvestro, L., Tafuto, S., Di Gennaro, E., Lastoria, S., Gallo, C., Perrone, F., Budillon, A., Piccirillo, M.C.

Get full text

Electrochemotherapy with bleomycin in locally advanced pancreatic adenocarcinoma by Leongito, M, Palaia, R, Albino, V, Di Giacomo, R, Amore, A, Piccirillo, M, Tafuto, S, Granata, V, Petrillo, A, Lastoria, S, Izzo, F

Get full text

Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score by Faggiano, A., Carratù, A. C., Guadagno, E., Tafuto, S., Tatangelo, F., Riccardi, F., Mocerino, C., Palmieri, G., Damiano, V., Siciliano, R., Leo, S., Mauro, A., Tozzi, L. F., Battista, C., De Rosa, G., Colao, A.

Get full text

P.02.5 METABOLIC SYNDROME IN COELIAC DISEASE: EFFECT OF THE GLUTEN-FREE DIET by Tortora, R, De Stefano, G, Imperatore, N, Capone, P, Tafuto, S, Gerbino, N, Leo, M, Caporaso, N, Rispo, A

Get full text

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial by Comella, P., Massidda, B., Filippelli, G., Palmeri, S., Natale, D., Farris, A., De Vita, F., Buzzi, F., Tafuto, S., Maiorino, L., Mancarella, S., Leo, S., Lorusso, V., De Lucia, L., Roselli, M.

“…Purpose:: The primary end point of this phase III trial was to compare the response rate (RR) of oxaliplatin (OXA) plus levo-folinic acid (l-FA) and…”
Get full text

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients : a Southern Italy Cooperative Oncology Group phase II study by COMELLA, P, MASSIDDA, B, PALMERI, S, FARRIS, A, DE LUCIA, L, NATALE, D, MAIORINO, L, TAFUTO, S, DE CATALDIS, G, CASARETTI, R

“…Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL…”
Get full text

1189P Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile by Di Mauro, A., Tatangelo, F., Tafuto, S., Cantile, M., Chianese, U., Benedetti, R., Conte, M., Cerrone, M., Scognamiglio, G., Nebbioso, A., Altucci, L.

Get full text

1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial by Clemente, O., Starita, N., Bracigliano, A., Cives, M., Tatangelo, F., Barretta, M.L., Badalamenti, G., Lastoria, S., Picozzi, F., Di Mauro, A., von Arx, C., Cannella, L., Tafuto, S.

Get full text

Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group by Comella, P., Crucitta, E., De Vita, F., De Lucia, L., Farris, A., Del Gaizo, F., Palmeri, S., Iannelli, A., Mancarella, S., Tafuto, S., Maiorino, L., Buzzi, F., De Cataldis, G.

“…Purpose The purpose of this study was to compare the activity and toxicity of the combination of irinotecan (IRI) plus folinic acid (FA)-modulated…”
Get full text

OC.06.3: ITANET NATIONAL PROSPECTIVE DATABASE: A COMPREHENSIVE ANALYSIS OF EPIDEMIOLOGY AND CLINICAL PRESENTATION OF GEP-NEN IN ITALY by Panzuto, F., Partelli, S., Campana, D., Pusceddu, S., Spada, F., Cives, M., Tafuto, S., Bertuzzi, A., Gelsomino, F., Rinzivillo, M., Marini, M., Falconi, M.

Get full text

1202P Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS) by von Arx, C., Cannella, L., Marretta, A.L., Bracigliano, A., Tatangelo, F., Clemente, O., Iervolino, D., Granata, V., Mocerino, C., Modica, R., Pizzolorusso, A., Bianco, A., Picozzi, F., Di Sarno, A., Tafuto, S.

Get full text

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment by Capozzi, Monica, De Divitiis, Chiara, Ottaiano, Alessandro, von Arx, Claudia, Scala, Stefania, Tatangelo, Fabiana, Delrio, Paolo, Tafuto, Salvatore

“…Lenvatinib is an emerging multi-kinase inhibitor with a preferential anti-angiogenic activity, which has shown efficacy in the treatment of renal cell…”
Get full text

1109P The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability by Lauricella, E., Cives, M., Felici, V., Bracigliano, A., S. lamia, Lippolis, R., Amoruso, B., Pelle, E., Esposto, C., Mandriani, B., Di Lorenzo, G., Clemente, O., Porta, C.G., Tafuto, S.

Get full text